The prognostic value of [ 18 F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria.
Christos SachpekidisVivienn WeruAnnette Kopp-SchneiderJessica C HasselAntonia Dimitrakopoulou-StraussPublished in: European journal of nuclear medicine and molecular imaging (2023)
In patients with metastatic melanoma PET/CT-based response assessment after four ICIs cycles is significantly associated with OS after application of different metabolic criteria. The prognostic performance of the modality is also high after the first two ICIs cycles, especially with employment of novel criteria. In addition, investigation of spleen glucose metabolism may provide further prognostic information.